Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University Medical Center, Richmond, VA, 23298-0204, USA.
Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, 77204, USA.
Mol Cell Biochem. 2020 May;468(1-2):47-58. doi: 10.1007/s11010-020-03710-0. Epub 2020 Mar 11.
Patients with metabolic syndrome (MetS) often exhibit generalized endothelial and cardiac dysfunction with decreased nitric oxide (NO) production and/or bioavailability. Since phosphodiesterase 5 (PDE5) inhibitors restore NO signaling, we hypothesized that chronic treatment with long-acting PDE5 inhibitor tadalafil may enhance plasma NO levels and reduce cardiac dysfunction following ischemia/reperfusion (I/R) injury in C57BL/6NCrl-Lepr/Crl mice with MetS phenotypes. Adult male MetS mice were randomized to receive vehicle solvent or tadalafil (1 mg/kg,i.p.) daily for 28 days and C57BL/6NCrl mice served as healthy wild-type controls. After 28 days, cardiac function was assessed by echocardiography and hearts from a subset of mice were isolated and subjected to 30 min of global ischemia followed by 60 min of reperfusion (I/R) in ex vivo Langendorff mode. Body weight, blood lipids, and glucose levels were elevated in MetS mice as compared with wild-type controls. The dyslipidemia in MetS was ameliorated following tadalafil treatment. Although left ventricular (LV) systolic function was minimally altered in the MetS mice, there was a significant diastolic dysfunction as indicated by reduction in the ratio of peak velocity of early to late filling of the mitral inflow, which was significantly improved by tadalafil treatment. Post-ischemic cardiac function, heart rate, and coronary flow decreased significantly in MetS mice compared to wild-type controls, but preserved by tadalafil treatment. Myocardial infarct size was significantly smaller following I/R, which was associated with higher plasma levels of nitrate and nitrite in the tadalafil-treated MetS mice. In conclusion, tadalafil induces significant cardioprotective effects as shown by improvement of LV diastolic function, lipid profile, and reduced infarct size following I/R. Tadalafil treatment enhanced NO production, which may have contributed to the cardioprotective effects.
患有代谢综合征(MetS)的患者通常表现出全身内皮和心脏功能障碍,导致一氧化氮(NO)产生和/或生物利用度降低。由于磷酸二酯酶 5(PDE5)抑制剂可恢复 NO 信号转导,我们假设长期给予长效 PDE5 抑制剂他达拉非可增强 MetS 表型的 C57BL/6NCrl-Lepr/Crl 小鼠缺血/再灌注(I/R)损伤后的血浆 NO 水平并减轻心脏功能障碍。成年雄性 MetS 小鼠随机接受溶剂载体或他达拉非(1mg/kg,腹腔注射)每日治疗 28 天,C57BL/6NCrl 小鼠作为健康野生型对照。28 天后,通过超声心动图评估心脏功能,并从一部分小鼠中分离心脏,在离体 Langendorff 模式下进行 30 分钟的整体缺血,然后进行 60 分钟的再灌注(I/R)。与野生型对照相比,MetS 小鼠的体重、血脂和血糖水平升高。MetS 中的血脂异常在他达拉非治疗后得到改善。尽管 MetS 小鼠的左心室(LV)收缩功能仅有轻微改变,但存在明显的舒张功能障碍,表现为二尖瓣流入道早期和晚期充盈峰值速度的比值降低,这一比值通过他达拉非治疗得到显著改善。与野生型对照相比,MetS 小鼠的缺血后心脏功能、心率和冠状动脉流量显著降低,但通过他达拉非治疗得到保留。与 I/R 相比,心肌梗死面积显著减小,这与他达拉非治疗的 MetS 小鼠血浆硝酸盐和亚硝酸盐水平升高有关。总之,他达拉非通过改善 LV 舒张功能、血脂谱和减少 I/R 后的梗死面积,诱导显著的心脏保护作用。他达拉非治疗增强了 NO 的产生,这可能有助于心脏保护作用。